Steroid Hormone Action and Cancer

  • K. M. J. Menon
  • Jerry R. Reel

Part of the Current Topics in Molecular Endocrinology book series (CTME, volume 4)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Marvin A. Rich, Philip Furmanski, Charles M. McGrath, Justin McCormick, Jose Russo, Herbert Soule
    Pages 15-27
  3. W. L. McGuire, K. B. Horwitz, M. De La Garza
    Pages 28-35
  4. L. E. Faber, J. Saffran, T. J. Chen, W. W. Leavitt
    Pages 68-84
  5. R. E. Counsell, A. Buswink, N. Korn, M. Johnson, V. Ranade, T. Yu
    Pages 107-113
  6. Thomas D. Gelehrter
    Pages 133-138
  7. Shutsung Liao, Stephen C. Hung, John L. Tymoczko, Tehming Liang
    Pages 139-151
  8. K. M. J. Menon
    Pages 172-175
  9. Back Matter
    Pages 176-182

About this book


This volume is an outgrowth of a symposium held at the University of Michigan, Ann Arbor, Michigan, October 27-29, 1975. This symposium was organized to bring together basic scientists and clinicians for the purpose of exchanging new ideas and the latest information in the area of Steroid Hormone Action and Cancer. The design of the symposium included both formal plenary sessions and informal roundtable discussion groups, the chapters of this volume being drawn primarily from these proceedings. During the last quarter of a century considerable progress has been made toward understanding the molecular mechanisms in­ volved in steroid hormone action. It now appears that the mechan­ sim of action of the four major classes of steroid hormones is qualitatively similar. Research during the past decade has demonstrated steroid hormone receptors in a variety of normal and neoplastic tissues. Receptor-containing neoplasms have been shown to be hormone-dependent and undergo regression when treated with hormone antagonists. Natural and synthetic steroids also have been employed for many years to successfully treat various types of cancer, for example: estrogens, androgens and progestagens for breast cancer; estrogens and progestagens for prostatic carcinoma; progestagens for endometrial carcinoma; and corticoids for leu­ kemias. All of these neoplasms have now been found to possess receptors for the steroids empirically used in their treatment.


hormone hormone receptors steroid steroids

Editors and affiliations

  • K. M. J. Menon
    • 1
  • Jerry R. Reel
    • 2
  1. 1.University of Michigan Medical SchoolAnn ArborUSA
  2. 2.Parke Davis Research LaboratoriesAnn ArborUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Internal Medicine & Dermatology